Textbook of Personalized Medicine - Second Edition [2015]

670

Table 22.1

Drugs with genetic information in their labels

Drug

Company

Indication

Genotype

Effect

Label

Abacavir

(Ziagen)

GlaxoSmithKline

HIV-1

HLA-B*5701

Hypersensitivity

Screening for the HLA-B*5701 allele

should be done prior to initiating therapy with abacavir

Azathioprine

(Imuran)

Prometheus

Renal allograft

transplantation

TPMT*2, TPMT*3A,

TPMT*3C

Severe myelotoxicity

TPMT genotyping can help identify

patients who are at an increased risk for developing Imuran toxicity

Carbamazepine

(Tegretol)

Novartis

Epilepsy, trigeminal

neuralgia

HLA-B*1502

Stevens-Johnson

syndrome (toxic epidermal necrolysis)

Patients in genetically at-risk populations

should be screened for HLA-B*1502 prior to initiating treatment and those testing positive not be treated with Tegretol

Cetuximab

(Erbitux)

Imclone

Metastatic colorectal

cancer

KRAS mutations

Effi

cacy

Use of Erbitux is not considered effective

for the treatment of patients colorectal cancer who have KRAS mutations in codon 12 or 13

Clopidogrel

(Plavix)

Bristol-Myers

Squibb

Anti-platelet:

prevents strokes and heart attacks

CYP2C19*2*3

Effi

cacy

Alternative treatment should be considered

for patients identifi ed as CYP2C19 poor metabolizers

Irinotecan

(Camptosar)

Pfi zer

Metastatic colorectal

cancer

UGT1A1*28

Diarrhea, neutropenia

A reduction in the starting dose by at least

one level of Camptosar should be considered for patients known to be homozygous for UGT1A1*28 allele

Panitumumab

(Vectibix)

Amgen

Metastatic colorectal

cancer

KRAS mutations

Effi

cacy

Vectibix is ineffective in patients whose

tumors have KRAS mutations

© Jain PharmaBiotech

22 Regulatory Aspects of Personalized Medicine